68 results
8-K
NMRA
Neumora Therapeutics Inc.
14 Jun 24
Submission of Matters to a Vote of Security Holders
4:01pm
of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 May 24
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:15am
and other neuropsychiatric disorders. The KOR antagonist approach has been clinically validated in three independent studies.
Neumora is currently
DEFA14A
3gdecze7t1
25 Apr 24
Additional proxy soliciting materials
4:15pm
DEF 14A
7v6pbd48
25 Apr 24
Definitive proxy
4:05pm
S-8
e89pp
7 Mar 24
Registration of securities for employees
4:34pm
S-8
EX-23.2
rgpbc7w33 q2z
7 Mar 24
Registration of securities for employees
4:34pm
10-K
7eb3h48jycx
7 Mar 24
Annual report
4:05pm
10-K
EX-10.23
8bexkegglj5j
7 Mar 24
Annual report
4:05pm
10-K
EX-23.1
fxfi7
7 Mar 24
Annual report
4:05pm
10-K
EX-10.22
jqragbyonwf2f1z 20m
7 Mar 24
Annual report
4:05pm
10-K
EX-97.1
o3ynxkkie 2paoy21
7 Mar 24
Annual report
4:05pm
8-K
EX-99.1
dtehtx71vsn yf8huys1
7 Mar 24
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023
7:08am
8-K
EX-99.1
szqrqk0zf
8 Jan 24
Regulation FD Disclosure
8:32am
S-8
EX-99.4
s3do6iy
19 Sep 23
Registration of securities for employees
9:57pm
S-8
EX-23.2
255cuqnmrl3sdwrgp
19 Sep 23
Registration of securities for employees
9:57pm
S-8
EX-99.3
eqf14gh4sw nro14
19 Sep 23
Registration of securities for employees
9:57pm
S-8
nbqdh xtp
19 Sep 23
Registration of securities for employees
9:57pm